Skip to main content

Weather Alert

Hurricane activity is severely impacting Quest locations across the Southeast. We ask that patients please double check your appointment status to ensure your designated Patient Service Center is operational.

Hide
Quest Diagnostics

Development and Validation of a 34-Gene Inherited Cancer Predisposition Panel Using Next-Generation Sequencing

Development and Validation of a 34-Gene Inherited Cancer Predisposition Panel Using Next-Generation Sequencing

Authors: Rosenthal SH, Sun W, Zhang K, Liu Y, Nguyen Q, Gerasimova A, Nery C, Cheng L, Castonguay C, Hiller E, Li J, Elzinga C, Wolfson D, Smolgovsky A, Chen R, Buller-Burckle A, Catanese J, Grupe A, Lacbawan F, Owen R

Citation: BioMed Res Int. 2020, https://doi.org/10.1155/2020/3289023 [Epub ahead of print]

Specialties: Oncology, Genetics

Download key summary

Related content

Conference Presentation
Frequency of Pathogenic and Likely Pathogenic Variants in Breast and Ovarian Cancer Genes Identified in a 34-Gene Hereditary Multi-Cancer Panel at a Diagnostic Reference Laboratory
Conference Presentation
Highly specific copy number variant flagging algorithm using next generation sequencing in cancer predisposition genes
Audio Podcast
Optimize Oncology Care with Clinical Pathways

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.